Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (EURTAC): A multicenter, open-label.; randomised phase 3 trial, Lancet Oncol, vol.13, pp.239-246, 2012. ,
First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N. Engl. J. Med, vol.371, pp.2167-2177, 2014. ,
Intergroupe Francophone de Cancérologie Thoracique. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial, Clin. Cancer Res, vol.18, pp.2976-2986, 2012. ,
RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non-Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway, Cancer Res, vol.76, pp.1627-1640, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02037182
NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells, J. Exp. Clin. Cancer Res, vol.38, pp.158-171, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02086738
A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer, Drugs, vol.54, pp.447-472, 1997. ,
How Taxol/paclitaxel kills cancer cells, Mol. Biol. Cell, vol.25, pp.2677-2681, 2014. ,
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: A meta-analysis of sur vival outcomes, Lung Cancer, vol.47, pp.69-80, 2005. ,
Paclitaxel for non-small cell lung cancer, Expert Opin. Pharmacother, vol.5, pp.1771-1780, 2004. ,
RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein, Mol. Cell, vol.27, pp.962-975, 2007. ,
The RASSFproteins in cancer; from epigenetic silencing to functional characterization, Biochim. Biophys. Acta, vol.1796, pp.114-128, 2009. ,
The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2, J. Biol. Chem, vol.286, pp.6253-6261, 2011. ,
Elucidation of a universal size-control mechanism in Drosophila and mammals, Cell, vol.130, pp.1120-1133, 2007. ,
RINGs and ubiquitylation, Nat. Rev. Mol. Cell Biol, vol.6, pp.287-297, 2005. ,
Elucidating respective functions of two domains BIR and C-helix of human IAP survivin for precise targeted regulating mitotic cycle.; apoptosis and autophagy of cancer cells, Oncotarget, vol.8, pp.113687-113700, 2017. ,
c-IAP1 cooperates with Myc by acting as a ubiquitin ligase for Mad1, Mol. Cell, vol.28, pp.914-922, 2007. ,
X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility, Nat. Cell Biol, vol.10, pp.1447-1455, 2008. ,
Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 transcription factor-mediated control of cyclin transcription, J. Biol. Chem, vol.286, pp.26406-26417, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-02337357
Regulation of cell migration, invasion and metastasis by IAP proteins and their antagonists, Oncogene, vol.33, pp.671-686, 2014. ,
IAPs and cell migration, Semin. Cell Dev. Biol, vol.39, pp.124-131, 2015. ,
Expression of Inhibitor of Apoptosis Proteins in Small-and Non-Small-Cell Lung Carcinoma Cells, Exp. Cell Res, vol.279, pp.277-290, 2002. ,
The inhibitors of apoptosis (IAPs) as cancer targets, Apoptosis, vol.12, pp.1543-1568, 2007. ,
Modulation of immune signalling by inhibitors of apoptosis, Trends Immunol, vol.33, pp.535-545, 2012. ,
IAP Antagonists Enhance Apoptotic Response to Enzalutamide in Castration-Resistant Prostate Cancer Cells via Autocrine TNF-? Signaling, Prostate, vol.77, pp.866-877, 2017. ,
Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations, Mol. Cancer Res, vol.11, pp.638-650, 2013. ,
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression, J. Natl. Cancer Inst, vol.93, pp.691-709, 2001. ,
MST1 promotes apoptosis through phosphorylation of histone H2AX, J. Biol. Chem, vol.285, pp.39108-39116, 2010. ,
A role for RASSF1A in tunneling nanotube formation between cells through GEFH1/Rab11 pathway control, Cell Commun. Signal, vol.16, pp.66-76, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02010920
Inhibitor of apoptosis-1 (IAP-1) expression and apoptosis in non-small-cell lung cancer cells exposed to gemcitabine, Biochem. Pharmacol, vol.1, pp.13-19, 2001. ,
LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC, J. Exp. Clin. Cancer Res, vol.35, pp.158-170, 2016. ,
cIAP1 Localizes to the nuclear compartment and modulates the cell cycle, Cancer Res, vol.65, pp.210-218, 2005. ,
The RASSF1 Gene and the Opposing Effects of the RASSF1A and RASSF1C Isoforms on Cell Proliferation and Apoptosis, Mol. Biol. Int, 2013. ,
Cellular migration and invasion uncoupled: Increased migration is not an inexorableconsequence of epithelial-to mesenchymal transition, Mol. Cell Biol, vol.34, pp.3486-3499, 2014. ,
IAP proteins: Regulators of cell migration and development, Curr. Opin. Cell Biol, vol.24, pp.871-885, 2012. ,
IAPs on the move: Role of inhibitors of apoptosis proteins in cell migration, Cell Death Dis, vol.4, pp.784-799, 2013. ,
Involvement of the RASSF1A tumor suppressor gene in controlling cell migration, Cancer Res, vol.65, pp.7653-7659, 2005. ,
Control of microtubule stability by the RASSF1A tumor suppressor, Oncogene, vol.22, pp.8125-8136, 2003. ,
RASSFIA interacts with microtubule-associated proteins and modulates microtubule dynamics, Cancer Res, vol.64, pp.4112-4116, 2004. ,
Insights into the mechanism of microtubule stabilization by Taxol, Proc. Natl. Acad. Sci, vol.103, pp.10166-10173, 2006. ,
Induction of apoptosis by cancer chemotherapy, Exp. Cell Res, vol.256, pp.42-49, 2000. ,
Ras signaling through RASSF proteins, Semin. Cell Dev. Biol, vol.58, pp.86-95, 2016. ,
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis, Nature, vol.376, pp.37-43, 1995. ,
The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death, Mol. Cell, vol.18, pp.637-650, 2005. ,
The RASSF1A tumor suppressor activates Bax via MOAP-1, J. Biol. Chem, vol.281, pp.4557-4563, 2006. ,
Dynamics of RASSF1A/MOAP-1 association with death receptors, Mol. Cell Biol, vol.28, pp.4520-4535, 2008. ,
RASSF1A promotes apoptosis and suppresses the proliferation of ovarian cancer cells, Int. J. Mol. Med, vol.33, pp.1153-1160, 2014. ,
The RASSF1A tumor suppressor restrains anaphase-promoting complex/cyclosome activity during the G1/S phase transition to promote cell cycle progression in human epithelial cells, Mol. Cell Biol, vol.28, pp.3190-3197, 2008. ,
Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 OS), J. Orthop. Res, vol.23, pp.988-994, 2005. ,
Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction, Breast Cancer Res. Treat, vol.133, pp.917-928, 2012. ,
The role of individual caspases in cell death induction by taxanes in breast cancer cells, Cancer Cell Int, vol.15, pp.8-17, 2015. ,
Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer, PLoS ONE, vol.9, p.109076, 2014. ,
Combination therapy of poly(ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells, J. Gastroenterol. Hepatol, vol.22, pp.738-748, 2007. ,
Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition gemcitabine.; and cisplatin, Cancer Res, vol.70, pp.7970-7980, 2010. ,
PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer, vol.7, pp.42319-42332, 2017. ,
RASSF1A and the Taxol Response in Ovarian Cancer, Mol. Biol. Int, pp.263267-263283, 2012. ,
A time to kill: Targeting apoptosis in cancer, Int. J. Mol. Sci, vol.16, pp.2942-2955, 2015. ,
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach, Cell, vol.125, pp.1253-1267, 2006. ,
Separating the anti-apoptotic and mitotic roles of survivin, J. Biol. Chem, vol.281, pp.33450-33466, 2006. ,
Enhancement of Gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the Survivin-T34A mutant, J. Extracell. Vesicles, vol.17, pp.3-24, 2014. ,
IAP regulation of metastasis, Cancer Cell, vol.17, pp.53-64, 2010. ,
Microtubule-associated protein 1s (MAP1S) bridges autophagic components with microtubules and mitochondria to affect autophagosomal biogenesis and degradation, J. Biol. Chem, vol.286, pp.10367-10377, 2011. ,
Functional importance of RASSF1A microtubule localization and polymorphisms, Oncogene, vol.29, pp.5729-5740, 2010. ,
Specificity of the methylation-suppressed A isoform of candidate tumor suppressor RASSF1 for microtubule hyperstabilization is determined by cell death inducer C19ORF5, Cancer Res, vol.65, pp.1830-1838, 2005. ,
Paclitaxel combined with harmine inhibits the migration and invasion of gastric cancer cells through downregulation of cyclooxygenase-2 expression, Oncol. Lett, vol.10, pp.1649-1654, 2015. ,
Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis, Int. J. Nanomed, vol.11, pp.1947-1958, 2016. ,
Low doses of Paclitaxel repress breast cancer invasion through DJ-1/KLF17 signalling pathway, Clin. Exp. Pharmacol. Physiol, pp.27-40, 2018. ,
Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells, Int. J. Oncol, vol.31, pp.277-283, 2007. ,
Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers, Mol. Cancer, vol.3, pp.8-43, 2009. ,
A randomised trial comparing preoperative to perioperative chemotherapy in earlystage non-small-cell lung cancer (IFCT 0002 trial), Eur. J. Cancer, vol.49, pp.2654-2664, 2013. ,
High TUBB3 expression.; an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy.; is regulated by K-Ras signaling pathway, Mol. Cancer Ther, vol.11, pp.1203-1213, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00718843
Ubiquitin-dependent regulation of MEKK2/3-MEK5-ERK5 signaling module by XIAP and cIAP1, EMBO J, vol.33, pp.1784-1801, 2014. ,
Cell cycle-dependent expression of cIAP2 at G2/M phase contributes to survival during mitotic cell cycle arrest, Biochem. J, vol.399, pp.335-342, 2006. ,
Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression, Proc. Natl. Acad. Sci, vol.107, pp.11936-11941, 2010. ,
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial, Oncotarget, vol.8, pp.4313-4329, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01550456
Multivariable prognostic models: Issues in developing models.; evaluating assumptions and adequacy, and measuring and reducing errors, Stat. Med, vol.5, pp.361-387, 1996. ,
Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: A systematic reviewand meta-analysis, JAMA Oncol, vol.4, pp.210-216, 2018. ,
Messengers of cell death: Apoptotic signaling in health and disease, Haematologica, vol.88, pp.212-218, 2003. ,
IAP-targeted therapies for cancer, Oncogene, vol.27, pp.6252-6275, 2008. ,
The IAP Protein Family, SMAC Mimetics and Cancer Treatment, Crit. Rev. Oncog, vol.21, pp.185-202, 2016. ,